Mersana Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2016 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Mersana Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2016 to Q4 2023.
  • Mersana Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $239M, a 25.6% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $239M +$48.9M +25.6% Dec 31, 2023 10-K 2024-02-28
Q4 2022 $191M +$60.5M +46.5% Dec 31, 2022 10-K 2024-02-28
Q4 2021 $130M +$52.7M +68.1% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $77.4M +$28.5M +58.3% Dec 31, 2020 10-K 2022-02-28
Q4 2019 $48.9M -$5.05M -9.36% Dec 31, 2019 10-K 2021-02-26
Q4 2018 $53.9M +$21.3M +65.5% Dec 31, 2018 10-K 2020-02-28
Q4 2017 $32.6M +$6.61M +25.4% Dec 31, 2017 10-K 2019-03-08
Q4 2016 $26M Dec 31, 2016 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.